De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Exagen Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

John Aballi

Algemeen directeur

US$932.0k

Totale compensatie

Percentage CEO-salaris	56.3%
Dienstverband CEO	2yrs
Eigendom CEO	1.2%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Sep 06

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Aug 07

Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Jul 13

Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

May 21

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Mar 26

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Mar 22

Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Apr 07

Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Mar 03

Exagen issues preliminary testing revenue ahead of ICT chat

Jan 11

Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Jan 05

Exagen (XGN) Investor Presentation - Slideshow

Nov 20

Analyse CEO-vergoeding

Hoe is John Aballi's beloning veranderd ten opzichte van Exagen's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$17m
Mar 31 2024	n/a	n/a	-US$19m
Dec 31 2023	US$932k	US$525k	-US$24m
Sep 30 2023	n/a	n/a	-US$32m
Jun 30 2023	n/a	n/a	-US$35m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$1m	US$111k	-US$47m

Compensatie versus markt: De totale vergoeding ($USD 931.95K ) John } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van John is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

John Aballi (39 yo)

2yrs

Tenure

US$931,950

Compensatie

Mr. John Aballi serves as President, Chief Executive Officer and Director at Exagen Inc. since October 17, 2022 and served as its Interim Chief Financial Officer since August 2024 until August 31, 2024. Mo...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Tina Nova	Executive Chairman of the Board of Directors	5.3yrs	US$132.81k	0% $ 0
John Aballi	CEO, President & Director	2yrs	US$931.95k	1.17% $ 584.6k
Kamal Adawi	Corporate Secretary	7.1yrs	US$915.09k	0.30% $ 151.0k
Ryan Douglas	Investors Relations Officer	no data	geen gegevens	geen gegevens
Andrew Concoff	Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board	2yrs	geen gegevens	geen gegevens
Michael Nerenberg	Chief Medical Officer	1.4yrs	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van XGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Tina Nova	Executive Chairman of the Board of Directors	5.3yrs	US$132.81k	0% $ 0
John Aballi	CEO, President & Director	2yrs	US$931.95k	1.17% $ 584.6k
Andrew Concoff	Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board	4.8yrs	geen gegevens	geen gegevens
Kenneth Bloom	Member of Breast Cancer Advisory Board	no data	geen gegevens	geen gegevens
Mark Pegram	Member of Breast Cancer Advisory Board	no data	geen gegevens	geen gegevens
Bruce Robertson	Independent Director	5.3yrs	US$33.75k	geen gegevens
Thomas Williams	Member of Breast Cancer Advisory Board	no data	geen gegevens	geen gegevens
Michael Press	Member of Breast Cancer Advisory Board	no data	geen gegevens	geen gegevens
Lyndsay Harris	Member of Breast Cancer Advisory Board	no data	geen gegevens	geen gegevens
Raymond Tubbs	Member of Breast Cancer Advisory Board	no data	geen gegevens	geen gegevens
Arthur Weinstein	Chairman of Scientific Advisory Board	4.8yrs	US$130.00k	geen gegevens
Frank Stokes	Independent Director	3.3yrs	US$82.70k	0% $ 0

4.8yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van XGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Exagen Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Exagen Inc. Announces Chief Financial Officer Changes

Exagen Inc. Announces Chief Financial Officer Changes

CEO, President & Director recently bought US$78k worth of stock

Exagen Inc., Annual General Meeting, Jun 10, 2024

Exagen Inc. Announces Changes in Board of Directors

CEO, President & Director recently sold US$59k worth of stock

Recent updates

Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Exagen Inc. Revises Earnings Guidance for the Full Year 2024

Exagen Inc. Announces Chief Financial Officer Changes

Exagen Inc. Announces Chief Financial Officer Changes

Exagen Inc. to Report Q2, 2024 Results on Aug 05, 2024

Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

Consensus estimates of losses per share improve by 13%

CEO, President & Director recently bought US$78k worth of stock

Exagen Inc. Updates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. to Report Q1, 2024 Results on May 13, 2024

Exagen Inc., Annual General Meeting, Jun 10, 2024

Exagen Inc. Announces Changes in Board of Directors

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. to Report Q4, 2023 Results on Mar 18, 2024

Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 11%

Exagen Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target decreased by 8.0% to US$5.75

CEO, President & Director recently sold US$59k worth of stock

New minor risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. to Report Q2, 2023 Results on Aug 07, 2023

Exagen Inc. Appoints Paul Kim as Class II Director

Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$1.92 loss, revenue downgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 38% to US$6.50

Exagen Inc. Announces Board Changes

Exagen Inc. Announces Executive Changes

Exagen Inc. Increases Revenue Guidance for 2022

Exagen Inc. announced delayed 10-Q filing

Exagen Inc. to Report Q3, 2022 Results on Nov 14, 2022

Exagen Inc. Appoints John Aballi as President

Exagen appoints John Aballi as CEO

Exagen Inc. Appoints Andrew L. Concoff as Chief Innovation Officer

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

Price target decreased to US$12.25

Consensus revenue estimates fall by 19%

Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Exagen Inc. Provides Revenue Guidance for the Year of 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Exagen Inc. to Report Q2, 2022 Results on Aug 04, 2022

Price target decreased to US$16.40

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. Revises Revenue Guidance for the Full Year of 2022

Price target decreased to US$18.00

Exagen Inc. to Report Q1, 2022 Results on May 11, 2022

Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Consensus EPS estimates fall by 12%

Price target decreased to US$21.00

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.34 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.38 loss per share (vs US$0.27 loss in 2Q 2020)

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Exagen Inc. Announces the Publication of Their Latest Clinical Utility Study in Lupus & Science Medicine

Price target increased to US$26.75

Independent Director Jeffrey Elliott has left the company

Independent Director Jeffrey Elliott has left the company

Consensus forecasts updated

First quarter 2021 earnings released: US$0.48 loss per share (vs US$0.44 loss in 1Q 2020)